Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Autologous CD19t T-APC |
Synonyms | |
Therapy Description |
Autologous CD19t T-APC are CD4 and CD8-positive antigen presenting cells (APCs) isolated from patients and engineered to express a truncated version of CD19, which may induce activation of CD19 chimeric antigen receptor (CAR)-expressing T-cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Autologous CD19t T-APC | Autologous CD19t T-antigen presenting cells | Autologous CD19t T-APC are CD4 and CD8-positive antigen presenting cells (APCs) isolated from patients and engineered to express a truncated version of CD19, which may induce activation of CD19 chimeric antigen receptor (CAR)-expressing T-cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03186118 | Phase I | Autologous CD19t T-APC | Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia | Active, not recruiting | USA | 0 |